Michael Lytton joined Oxford Bioscience Partners in January 2001. Prior to that, he was Partner, Chairman of the Technology Group, and a member of the Executive Committee of Palmer & Dodge LLP, a Boston-based law firm.
Mr. Lytton serves on the Boards of Directors of Alantos, Claros Diagnostics, Inc., Decision Biomarkers, Enanta, GPC Biotech, Radius, Rib-X, Santhera, and VaxInnate. Mr. Lytton was also responsible for investments by Oxford in Aveo and Concentric. Mr. Lytton is Chairman of the Research and Technology Committee of the Center for Blood Research, Harvard Medical School, where he is also a member of the Board of Trustees. Mr. Lytton also serves on the Board of Directors of the non-profit organization, Medicines in Need, a Harvard-based foundation sponsoring clinical development of a novel drug delivery technology to be used for medicines supplied to developing world countries. In addition, he serves on the Advisory Committee to Connecticut Innovations, a public agency funding early-stage biomedical companies in Connecticut.
Mr. Lytton periodically contributes to a quarterly column on issues facing early-stage biomedical companies for Start-Up magazine, published by Windhover Information. Mr. Lytton has served on the Executive Board of the MIT Enterprise Forum and the Patent Committee of the Boston University Medical Center. He was a summa cum laude graduate of The Woodrow Wilson School of Public and International Affairs, Princeton University and a recipient of a Fulbright Scholarship for study at the University of London, and he received a J.D. degree cum laude from Harvard Law School. Mr. Lytton also received a M.Sc. degree in Epidemiology and Medical Statistics from the London School of Hygiene and Tropical Medicine.
